The Filing Desk

Invivyd vs Q32 Bio

Invivyd IVVD · Q32 Bio QTTB · Biotechnology

Q32 Bio reported revenue of $54 million in fiscal 2025, about the same as Invivyd's $53 million in fiscal 2025. Invivyd had an operating margin of -104.0%, against 31.4% at Q32 Bio. Free cash flow was −$58 million at Invivyd and −$34 million at Q32 Bio.

Side by side

InvivydQ32 Bio
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$53M$54M
Revenue growth110.5%—
Revenue growth a year, last 5 years—81.9%
Gross margin——
Operating margin−104.0%31.4%
Net margin−98.2%55.5%
Free cash flow−$58M−$34M
Free cash flow margin−109.1%−62.4%
Return on capital——
Net debt to EBITDA—−2.8x
Dividends and buybacks$0M$0M
Change in diluted share count45.3%27.5%
Last close$0.45$8.48
P/E at the last close—10.5×
Insider trades, last 12 monthssold $341,120—
Piotroski F-score—3 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
InvivydQ32 Bio
Operating margin
Percent of revenue
InvivydQ32 Bio
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
InvivydQ32 Bio

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Invivyd and Q32 Bio pages.